Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(8%)
Results Posted
50%(3 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
1
8%
Ph phase_1
1
8%
Ph phase_2
5
38%
Ph phase_4
4
31%
Ph not_applicable
2
15%

Phase Distribution

1

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
4(30.8%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(6)
Terminated(3)
Other(3)

Detailed Status

Completed6
unknown3
Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 25 (38.5%)
Phase 31 (7.7%)
Phase 44 (30.8%)
N/A2 (15.4%)

Trials by Status

completed646%
unknown323%
withdrawn18%
terminated215%
recruiting18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13